Your session is about to expire
← Back to Search
Dalfampridine for ALS
Study Summary
This trial will study the safety and tolerability of a new medication for people with primary lateral sclerosis or upper motor neuron predominate ALS. A total of 35 subjects will be enrolled and will be given the medication to take for 18 weeks. The study will measure the subjects' ability to walk during that time period. A consistent responder will be defined as improvement in 3 of 4 Timed 25Foot Walk while on medication, compared with the baseline results while off medication.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had active cancer in the last 2 years, except for treated skin cancer.I have a condition affecting my brain's nerve cells, showing symptoms in at least 2 body areas.I have a history of seizures or any metal implants above the neck.I am willing and able to sign the informed consent.I am mentally capable of understanding and following the trial's procedures.I haven't taken any drugs for PLS or ALS in the last 30 days.I have some difficulty walking but can still walk.I have received or will receive botulinum toxin in my legs within the last 6 months.I am between 18 and 99 years old.I am not pregnant, breastfeeding, or trying to conceive.You have misused drugs or alcohol in the past year.I do not have serious liver, kidney diseases, nerve issues, or certain genetic conditions.I am allergic to pyridine or ingredients in dalfampridine tablets.I cannot become pregnant or am using effective birth control.You have not had an allergic reaction to dalfampridine before.My kidney function is reduced with a creatinine clearance of ≤50 mL/min.You must be able to breathe out a certain amount of air, at least 60% of what is expected for someone your age and size.Your lab test results show significant health problems.Your symptoms started more than 18 months ago.I haven't taken Riluzole in the last 30 days or am on a stable dose.You had a test within the last 3 months that shows little or no sign of a specific kind of nerve disease.
- Group 1: Ampyra
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the cap for participant enrollments in this clinical trial?
"As of September 30th 2022, this trial is no longer recruiting. Initially posted on March 1st 2016, the study has since been completed or suspended. If you are looking for other trials involving motor neuron disease and upper dalfampridine, there are 134 studies and 5 studies respectively actively seeking participants."
Has dalfampridine satisfied the FDA's regulatory criteria for public use?
"Considering the sparse evidence of efficacy and safety, dalfampridine was given a rating of 1 on our risk scale."
Does this clinical research currently have availability for participants?
"According to clinicaltrials.gov, this investigation is not presently accepting new trial participants. Originally posted on March 1st 2016 and updated lastly on September 30th 2022, the study no longer needs candidates; however there are 139 other studies that still require enrolment."
Could you elaborate on any other research experiments that have been carried out with dalfampridine?
"First trialled in 2016 at Shara Holzberg, dalfampridine has since then been the subject of 36 completed medical studies. Five additional trials are currently underway with many occurring in Boston, Massachusetts."
What are the criteria for a potential participant in this experiment?
"To be considered for participation in this clinical trial, interested parties must have upper-body motor neuron disease and meet the age criteria of 18 to 99 years old. A total of 35 participants are sought after."
Is there an upper age limit for participants in this experimental protocol?
"This clinical trial is open to participants of legal age (18+) and up to 99 years old."
Share this study with friends
Copy Link
Messenger